Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis, treatment and follow-up of patients with early breast cancer.

20 For ESMO ‘recommendation 5h’ the benefit of the addition of pertuzumab to trastuzumab for the adjuvant treatment of patients with HER2-positive breast cancer was discussed based on the findings of the phase III APHINITY trial, where the OS benefit at both the 6-year (HR = 0.85; 95% CI = 0.67-1.07; P = 0.17) and 8-year (HR = 0.83; 95% CI = 0.68-1.02; P = 0.078) follow-up failed to reach statistical significance. 49 , 50 There was, however, a consistent improvement in iDFS where 88.4% of patients in the pertuzumab group versus 85.8% of patients in the placebo group were event-free at the 8-year follow-up, which corresponded to an absolute benefit of 2.6% (95% CI for the difference = 0.7-4.6). 49 Subgroup a

also in 6,035 other papers